Amicus Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Strong revenue growth and profitability were highlighted, with Galafold and Pombiliti/Opfolda driving expansion in rare disease markets. The pipeline advanced with the DMX-200 FSGS program, and financial discipline remains a priority as the company eyes further late-stage asset deals.
-
Strong financial performance and product growth are driven by increased diagnosis, global expansion, and robust real-world data. Key catalysts include IP litigation outcomes, label expansions, and DMX-200 trial progress, with a focus on rare disease markets and stable pricing.
-
Q3 2025 saw 19% revenue growth, GAAP profitability, and record demand for Galafold and Pombiliti/Opfolda. Guidance for 2025 was reiterated, with strong growth expected in both core products and continued pipeline progress, including DMX-200 for FSGS.
-
Strong Q2 sales and robust growth in rare disease therapies are driving a path to GAAP profitability by late 2025. Expansion of Galafold and Pombiliti/Opfolda continues globally, while pipeline and BD efforts focus on late-stage, high-potential assets.
-
Strong commercial growth continues for both Fabry and Pompe therapies, with Galafold maintaining high market share and compliance. Pipeline expansion includes DMX-200 for FSGS, supported by positive interim data and regulatory alignment. Profitability and further pipeline additions are expected in the near term.
-
Q2 2025 saw 22% revenue growth, driven by Galafold and Pombiliti/Opfolda, with strong global expansion and robust patient demand. Guidance for 2025 is reiterated, with positive GAAP net income expected in the second half and continued investment in late-stage assets like DMX-200.
-
Strong growth in rare disease therapies is driven by Galafold and Pombiliti/Opfolda, with new launches and expanding diagnosis rates fueling momentum. Financial discipline, minimal macro risk, and a smartly structured DMX-200 deal support profitability and future pipeline expansion.
-
Sustained double-digit growth in core products is driven by patient volume, expanded diagnostics, and strong market share. Profitability milestones are being met, with new AI initiatives and a strategic FSGS acquisition supporting future growth.
-
Recent policy changes and tariffs are manageable, with Galafold's growth driven by increased diagnosis and AI initiatives. POMOP is accelerating in the U.S. and Europe, benefiting from patient switches and strong market positioning. The DMX-200 acquisition fits a disciplined, infrastructure-leveraging strategy.
-
Q1 2025 saw 13% revenue growth, strong performance in Fabry and Pompe, and a strategic Dimerix deal. Guidance for Pombiliti and Opfolda was revised due to UK rebates and timing of patient starts, but profitability is expected in H2 2025.
-
Commercial launches for Pombiliti are expanding across Europe and the U.S., with strong growth also seen in Galafold driven by improved diagnostics and new patient identification. Financial performance exceeded expectations, with profitability milestones reached and further growth anticipated through new market entries and pipeline expansion.
-
Strong growth is projected for both Galafold and Pombiliti Opfolda, with robust insurance coverage and expanding prescriber base. Competitive differentiation is driven by data and real-world evidence, while regulatory and pipeline efforts focus on pediatric expansion and novel delivery technologies. Commercial strategy leverages global infrastructure for future asset integration.
-
Strong revenue growth and profitability were achieved, with projections to surpass $1 billion in global sales by 2028. Galafold and Pombiliti/Opfolda are driving expansion through market penetration, geographic launches, and label extensions, supported by robust IP and diagnostic initiatives.
Fiscal Year 2024
-
Revenue grew 32% to $528M in 2024, led by Galafold and Pombiliti/Opfolda, with non-GAAP profitability achieved. 2025 guidance projects 17%-24% revenue growth, double-digit expansion for both therapies, and positive GAAP net income in H2.
-
Strong growth continues for both Galafold and Pombiliti/Opfolda, with raised guidance and expanding market presence. Profitability has been achieved, and further launches are planned, while Galafold’s long-term outlook is secured by patent protection.
-
Strong revenue growth and profitability were highlighted, with raised guidance for Pombiliti+Opfolda and continued expansion of Galafold. Patent exclusivity for Galafold was extended, and strategic focus remains on new market launches, business development, and pipeline expansion.
-
Q3 2024 revenue grew 37% year-over-year to $142 million, driven by strong Galafold and Pombiliti/Opfolda performance. Full-year revenue and product guidance were raised, and non-GAAP profitability was achieved. Tight cost control and global expansion support continued growth.
-
Patient switching and durable outcomes support strong growth for both Pompe and Fabry therapies, with expanding diagnosis rates and new market launches fueling future revenue. Strategic focus on execution, value-based pricing, and pipeline expansion positions the business for continued upside.
-
Galafold and Pombiliti/Opfolda are driving strong revenue growth, with expanded market share in rare diseases and improved patient access. Manufacturing transitions and cost reductions are on track, while future growth will focus on label expansion, pipeline development, and disciplined financial management.
-
Q2 2024 revenue grew 34% year-over-year to $127 million, driven by strong Galafold and Pombiliti/Opfolda performance. Full-year revenue and Galafold growth guidance were raised, and non-GAAP profitability was achieved in Q2 and the first half, with continued momentum expected.
-
Strong commercial execution is driving 25%-30% revenue growth, with both core products targeting $1B peak sales. Pombiliti/Opfolda is gaining share globally, while Galafold maintains robust growth. Manufacturing and regulatory strategies are in place to ensure long-term resilience.